Education
About Us
Working with TipRanks
Follow Us
Gt Biopharma, Inc. (GTBP)
NASDAQ:GTBP
Total Valuation
GT Biopharma has a market cap or net worth of $8.05M. The enterprise value is -$308.77K.
Market Cap$8.05M
Enterprise Value-$308.77K
Share Statistics
GT Biopharma has 10,636,135 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding10,636,135
Owned by Insiders8.05%
Owned by Institutions1.53%
Financial Efficiency
GT Biopharma’s return on equity (ROE) is 7.88 and return on invested capital (ROIC) is 860.12%.
Return on Equity (ROE)7.88
Return on Assets (ROA)-3.11
Return on Invested Capital (ROIC)860.12%
Return on Capital Employed (ROCE)8.60
Revenue Per Employee0.00
Profits Per Employee-13.16M
Employee Count1
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of GT Biopharma is ―. GT Biopharma’s PEG ratio is -0.02.
PE Ratio―
PS Ratio0.00
PB Ratio-3.46
Price to Fair Value-3.46
Price to FCF-0.45
Price to Operating Cash Flow-0.26
PEG Ratio-0.02
Income Statement
In the last 12 months, GT Biopharma had revenue of 0.00 and earned -13.16M in profits. Earnings per share was -6.94.
Revenue0.00
Gross Profit0.00
Operating Income-14.36M
Pretax Income-13.16M
Net Income-13.16M
EBITDA-13.16M
Earnings Per Share (EPS)-6.94
Cash Flow
In the last 12 months, operating cash flow was -11.36M and capital expenditures 0.00, giving a free cash flow of -11.36M billion.
Operating Cash Flow-11.36M
Free Cash Flow-11.36M
Free Cash Flow per Share-1.07
Dividends & Yields
GT Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.34
52-Week Price Change-75.94%
50-Day Moving Average0.69
200-Day Moving Average1.67
Relative Strength Index (RSI)57.15
Average Volume (3m)1.50M
Important Dates
GT Biopharma upcoming earnings date is Apr 1, 2026, TBA (Confirmed).
Last Earnings DateNov 4, 2025
Next Earnings DateApr 1, 2026
Ex-Dividend Date―
Financial Position
GT Biopharma as a current ratio of 0.72, with Debt / Equity ratio of 0.00%
Current Ratio0.72
Quick Ratio0.72
Debt to Market Cap0.00
Net Debt to EBITDA0.30
Interest Coverage Ratio0.00
Taxes
In the past 12 months, GT Biopharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
GT Biopharma EV to EBITDA ratio is -0.14, with an EV/FCF ratio of -0.14.
EV to Sales0.00
EV to EBITDA-0.14
EV to Free Cash Flow-0.14
EV to Operating Cash Flow-0.14
Balance Sheet
GT Biopharma has $2.62M in cash and marketable securities with $0.00 in debt, giving a net cash position of $2.62M billion.
Cash & Marketable Securities$2.62M
Total Debt$0.00
Net Cash$2.62M
Net Cash Per Share$0.25
Tangible Book Value Per Share-$0.88
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for GT Biopharma is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.00
Price Target Upside995.89% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast54.62%